Prostate Cancer Clinical Trial
Official title:
Impact of Yoga As Complementary Therapy on Quality of Life, Pro-inflammatory, and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized-Controlled Trial
Verified date | January 2022 |
Source | The University of Texas Health Science Center at San Antonio |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The researchers hope to learn if yoga complementary therapy would improve health-related quality of life, recovery of urinary continence and erectile function in patients who underwent prostate cancer surgery (i.e. radical prostatectomy). We hypothesized that in patients undergoing radical prostatectomy, preoperative and postoperative Yoga complementary therapy would improve health- related quality of life (HRQOL), recovery of urinary continence and erectile function. This two-arm, randomized controlled pilot study will compare Yoga intervention to usual care group. The aim is to evaluate the efficacy of Yoga complementary therapy on HRQOL in patients who underwent radical prostatectomy (RP). Yoga therapy will be given to the intervention group three times in a week for 6 weeks prior to surgery and then initiated 3 weeks after the surgery for another 6 weeks. The yoga exercise will be tailored to the participant's comfort level. As an exploratory analysis, we will evaluate pro-inflammatory and immunological markers.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 31, 2021 |
Est. primary completion date | June 29, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Men between the age of 30 to 80 - Has been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed) - Is scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach) - Has no other active primary malignancy aside from prostate cancer - Currently not practicing yoga as a form of exercise and/or meditation - Does not have uncontrolled pain - Does not have neurological or musculoskeletal co-morbidity inhibiting exercise - Has never been diagnosed by health care professionals to have absolute contraindications to exercise testing - Willing to be randomized to either standard care or intervention group - Willing to participate in yoga therapy for twelve weeks if randomized to intervention group - Willing to undergo phlebotomy - Able and willing to provide informed consent Exclusion Criteria: - Men under the age of 30 or over the age of 80 - Has NOT been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed) - Is NOT scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach) - Has other active primary malignancy aside from prostate cancer - Currently practicing yoga as a form of exercise and/or meditation - Has uncontrolled pain - Has neurological or musculoskeletal co-morbidity inhibiting exercise - Has been diagnosed with psychotic, addictive, and major cognitive disorders - Has been diagnosed by health care professionals to have absolute contraindications to exercise testing Unwilling to be randomized to either standard care or intervention group - Unwilling to participate in yoga therapy for twelve weeks if randomized to intervention group - Unwilling to undergo phlebotomy - Unable and unwilling to provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center at San Antonio |
United States,
Kaushik D, Shah PK, Mukherjee N, Ji N, Dursun F, Kumar AP, Thompson IM Jr, Mansour AM, Jha R, Yang X, Wang H, Darby N, Ricardo Rivero J, Svatek RS, Liss MA. Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot random — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in health related quality of life measures | health related quality of life measures including but not limited to fatigue level, recovery urinary continence, and erectile function. | One year | |
Primary | Change from baseline in 6-minute walk test | One year | ||
Primary | Total number of participants recruited to and withdraw from the study | One year | ||
Primary | Total number of participants completed the study | One year | ||
Primary | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 | One year | ||
Secondary | Change from baseline level on pro-inflammatory biomarkers | one year | ||
Secondary | Change from baseline level on cellular immune response (i.e. measuring the Natural Killer Cell and regulatory-T cells) | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |